ArticleClinical, cosmetic and investigational dermatology2025
Clinical Characteristics and Disease Course of Livedoid Vasculopathy: A 10-Year Retrospective Analysis.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Livedoid vasculopathy (LV) is a rare, chronic, recurrent thrombo-occlusive cutaneous disorder, which is also known as atrophie blanche (AB). Its characteristic clinical manifestations include livedo racemosa, painful ulcerations, and white atrophic scars predominantly on the lower extremities. This study aimed to investigate the clinical appearance, histological features and laboratory test results, treatment strategies, and clinical outcomes of LV to provide evidence for clinical diagnosis and management. Methods: We conducted a retrospective analysis of clinical data from 69 LV patients diagnosed in the First Affiliated Hospital of Sun Yat-sen University between January 2014 and December 2024. Data encompassed demographic characteristics, clinical manifestations, histopathological features, laboratory investigations, treatment regimens, and follow-up results. Treatment efficacy was assessed based on ulcer healing time and patient-reported symptom improvement. Results: The median age was 31 years (range: 11-85 years), with females constituting 69.6% (48/69). Only 5 patients (7.3%, 5/69) received an initial diagnosis of LV. The predominant clinical presentations were recurrent painful ulcerations (89.9%, 62/69), white atrophic scars (82.6%, 57/69), purpura (84.1%, 58/69), livedo racemosa (75.4%, 52/69) and local pain (85.5%, 59/69) on the lower extremities. Treatment modalities primarily included anticoagulant therapy, antiplatelet therapy, corticosteroids, lipid-lowering therapy, immunosuppressive agents, traditional Chinese medicine and physical therapy modalities. Conclusion: LV predominantly affects young and middle-aged females. Combination therapy with anticoagulant, antiplatelet and corticosteroids significantly contributes to ulcer healing and rapid pain relief. Long-term follow-up is necessary to monitor for potential progression to systemic diseases. As a single-center retrospective study, these findings warrant further validation through multicenter prospective research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.